[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354262-105":59,"doc-detail-354262-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mir-17-from-developmental-regulatory-hub-to-molecular-engine-driving-tumourigenesis","miR-17: from developmental regulatory hub to molecular engine driving tumourigenesis","","miR-17 is an oncogenic microRNA driving initiation and progression across multiple malignant tumours, including lymphoma, lung cancer, colorectal cancer, and breast cancer. It suppresses apoptosis pathway activation and promotes G1/S cell-cycle transition by targeting tumour suppressors and cell-cycle regulators. miR-17 also enhances invasion and migration via EMT-related signalling, including PI3K/AKT and Wnt/β-catenin, and modulates non-coding RNA networks by acting as a sponge and influencing stability/biogenesis. These effects contribute to therapy resistance, tumour angiogenesis, and improved diagnostic potential as a non-invasive biomarker. Restoring miR-17 may improve prognosis, yet its full mechanism remains incompletely understood.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mir-17-from-developmental-regulatory-hub-to-molecular-engine-driving-tumourigenesis/354262/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mir-17-from-developmental-regulatory-hub-to-molecular-engine-driving-tumourigenesis/354262.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biological processes does miR-17 influence in tumour cells?","Question",{"text":112,"@type":113},"miR-17 inhibits apoptosis pathway activation and promotes the G1/S phase transition, supporting unlimited proliferation of tumour cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does miR-17 enhance tumour invasiveness and migration?",{"text":117,"@type":113},"It targets molecules linked to EMT and activates key signalling pathways such as PI3K/AKT and Wnt/β-catenin, increasing invasiveness and migration.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is miR-17 considered promising for clinical use?",{"text":121,"@type":113},"miR-17 has potential for early cancer diagnosis, particularly as a non-invasive biomarker in lung and gastric cancers, and restoring its expression may improve outcomes by enhancing therapy efficacy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354262,1790472793,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Mini Review  \nPUBLISHED 20 May 2026  \nDOI 10.3389/fonc.2026.1787691  \nOPEN ACCESS  \nEDITED BY  \nKentaro Minagawa, The Pennsylvania State University, United States  \nREVIEWED BY  \nZohreh Mirzaei,  \nTabriz University of Medical Sciences, Iran  \n*CORRESPONDENCE  \nFeng Hui Wang  \n[xsybz930612@126.com](xsybz930612@126.com)  \nRECEIVED 14 January 2026  \nREVISED 23 March 2026  \nACCEPTED 27 March 2026  \nPUBLISHED 20 May 2026  \nCORRECTED 15 June 2026  \nCITATION  \nZhang M, Ma Y, Chen X, Sun T, Wang XY and Wang FH (2026) miR-17: from developmental regulatory hub to molecular engine driving tumourigenesis.  \nFront. Oncol. 16:1787691 .  \ndoi: 10.3389/fonc.2026.1787691  \nCOPYRIGHT  \n© 2026 Zhang, Ma, Chen, Sun, Wang and Wang. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nmiR-17: from developmental regulatory hub to molecular engine driving tumourigenesis  \nMin Zhang, Yurong Ma, XuanYu Chen, Tiansi Sun, XiYi Wang and Feng Hui Wang*  \nYan ’an Medical College of Yan’an University, Yan’an, Shaanxi, China  \nMicroRNA-17(miR-17) is a prototypical oncogenic miRNA that plays a central driving role in the initiation and progression of various malignant tumours (MT), including lymphoma, lung cancer, colorectal cancer (CRC), and breast cancer (BC) . It inhibits the activation of apoptosis pathways and promotes the G1/S phase transition by targeting tumor suppressor genes and cell cycle regulators, thereby driving the unlimited proliferation of tumor cells. Concurrently, it targets molecules associated with epithelial-mesenchymal transition (EMT), activating key signalling pathways, such as Phosphatidylinositol 3-Kinase/Protein Kinase B (PI3K/AKT) and Wnt/Beta-catenin(Wnt/b-catenin) to enhance the invasiveness and migration capabilities of tumour cells. Moreover, miR-17 participates in across-regulatory network of non- coding RNAs(ncRNAs), acting both as a molecular sponge to sequester long non-coding RNAs(lncRNAs) and circular RNAs(circRNAs), and as a regulator of the stability or biogenesis of these ncRNAs.This further ampliﬁes oncogenic effects, induces tumor cell resistance to chemotherapy and radiotherapy, and ultimately synergistically promotes tumor angiogenesis, thereby remodeling the tumor microenvironment(TME) . In clinical applications, miR-17 holds potential for early cancer diagnosis, particularly serving as a non-invasive biomarker in lung and Gastric cancers (GC) . As a therapeutic target, restoring miR-17 expression via targeted interventions enhances. The efﬁcacy of chemotherapy or targeted therapy thereby improves patient prognosis. Despite extensive research in this ﬁeld, the precise mechanism of action for miR-17 remains incompletely understood. This review summarizes the current state of research concerning the relationship between miR-17 and its target genes in MT, as well as the underlying mechanisms involved.  \nKEYWORDS  \ndiagnostic markers, miR-17, signalling pathways, target genes, tumor biology  \n1 Introduction  \nDespite advances in cancer prevention, early detection, and treatment, cancer remains a major unresolved medical challenge worldwide. In 2022, nearly 20 million new cancer cases were diagnosed globally, with approximately 9.7 million deaths. China recorded 4.8247 million new cases and 2.5742 million deaths, ranking ﬁrst in the world for both metrics (1) . The ﬁve leading causes of cancer deaths in China are lung cancer, liver cancer (LC), GC, CRC, and oesophageal cancer (EC) . Among these, LC mortality rose from third place in  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \n2018 to second place in ","cbCaifpz0y2c4wEG","https://ap.wps.com/l/cbCaifpz0y2c4wEG","pdf",1946137,15,"English","# 1 Introduction\n## MicroRNA-17 and oncogenic roles\n## Epidemiological context and cancer challenges\n## Overview of ncRNAs and miRNA function","[{\"question\":\"What biological processes does miR-17 influence in tumour cells?\",\"answer\":\"miR-17 inhibits apoptosis pathway activation and promotes the G1/S phase transition, supporting unlimited proliferation of tumour cells.\"},{\"question\":\"How does miR-17 enhance tumour invasiveness and migration?\",\"answer\":\"It targets molecules linked to EMT and activates key signalling pathways such as PI3K/AKT and Wnt/β-catenin, increasing invasiveness and migration.\"},{\"question\":\"Why is miR-17 considered promising for clinical use?\",\"answer\":\"miR-17 has potential for early cancer diagnosis, particularly as a non-invasive biomarker in lung and gastric cancers, and restoring its expression may improve outcomes by enhancing therapy efficacy.\"}]","miR-17: from developmental regulatory hub to molecular engine driving tumourigenesis | PDF",1790109755,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69c7d7571b69a2bf81d2dce946d9efab.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea36a76f6d441699732a87c87a101bce.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88bcb290e2d347c1e998e141f9bd2d82.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9876d6657ec93eda215c18b8ea063b8c.webp",980,1385]